Skip to main content
Erschienen in: Clinical and Translational Oncology 8/2017

01.03.2017 | Correspondence

Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis

verfasst von: E. Rodríguez-Lomba, I. Marquez-Rodas, E. Mercader-Cidoncha, R. Suárez-Fernández, J. A. Avilés-Izquierdo

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Excerpt

Although tumor thickness has proven to be the strongest predictor for disease-free and overall survival in patients with primary cutaneous melanoma, it has been noted that not all patients with thick melanoma (>4 mm tumor thickness) die from disease progression . To this date, few studies regarding the epidemiological features of patients with thick melanoma have been reported [1]. Our knowledge on which factors, besides tumor thickness, are responsible for the differences in these patients’ prognosis is currently limited. …
Literatur
1.
Zurück zum Zitat Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, et al. Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. Arch Dermatol. 2012;148:1370–6.CrossRef Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, et al. Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. Arch Dermatol. 2012;148:1370–6.CrossRef
2.
Zurück zum Zitat Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016;75:967–74.CrossRef Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016;75:967–74.CrossRef
3.
Zurück zum Zitat Joosse A, Collete S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survical in metastasized stage III to IV melanoma: a pooled analysis of five European organization for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013;31:2337–46.CrossRef Joosse A, Collete S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survical in metastasized stage III to IV melanoma: a pooled analysis of five European organization for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013;31:2337–46.CrossRef
4.
Zurück zum Zitat Avilés-Izquierdo JA, Lázaro-Ochaita P. Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol. 2012;14:237–40.CrossRef Avilés-Izquierdo JA, Lázaro-Ochaita P. Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol. 2012;14:237–40.CrossRef
5.
Zurück zum Zitat Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23:938–45.CrossRef Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23:938–45.CrossRef
Metadaten
Titel
Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis
verfasst von
E. Rodríguez-Lomba
I. Marquez-Rodas
E. Mercader-Cidoncha
R. Suárez-Fernández
J. A. Avilés-Izquierdo
Publikationsdatum
01.03.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 8/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1637-y

Weitere Artikel der Ausgabe 8/2017

Clinical and Translational Oncology 8/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.